MyHep All – Generic Epclusa

Description

MyHep All is a powerful fixed-dose combination medication manufactured by Mylan Pharmaceuticals for the treatment of chronic Hepatitis C in adults. It contains Sofosbuvir 400 mg, a nucleotide polymerase inhibitor, and Velpatasvir 100 mg, an NS5A inhibitor. Together, these direct-acting antivirals (DAAs) stop the virus from multiplying and eliminate it from the body.

Approved for treatment across all six major genotypes (genotype 1-6) of HCV, MyHep All simplifies therapy by offering a pangenotypic, once-daily oral tablet—no need for interferon or ribavirin in most cases. The standard treatment duration is 12 weeks, often resulting in a sustained virologic response (SVR), which is considered a cure.

Key Features:

• Pangenotypic – treats all genotypes of Hepatitis C
• High cure rate (SVR) after a 12-week course
• Once-daily oral tablet for ease of use
• Minimal side effects in most patients
• Manufactured by the trusted brand Mylan

Usage & Dosage:

• Dosage: One tablet daily, with or without food
• Treatment duration: Typically 12 weeks
• Always take the medication exactly as prescribed. Continue to use for the full prescribed length of time, even if symptoms improve earlier.

Precautions:

• Not recommended for use in patients with severe kidney disease without physician approval
• Not for use during pregnancy or breastfeeding unless advised by a healthcare provider
• Inform your doctor about all current medications to avoid drug interactions
• Regular liver function and viral load tests are needed during treatment

Storage Instructions:

• Store at room temperature (15°C to 30°C)
• Keep away from moisture and direct sunlight
• Keep out of reach of children

FAQs – MyHep All

Q1: What is MyHep All used for?
A: MyHep All is used to treat chronic Hepatitis C virus (HCV) infection in adults. It is an effective pangenotypic treatment, meaning it works across all genotypes (1–6) of the HCV virus.

Q2: How effective is MyHep All?
A: Clinical studies have shown cure rates (SVR – sustained virologic response) of over 95% after a 12-week treatment, even in patients with cirrhosis or those previously treated without success.

Q3: What are the main ingredients in MyHep All?
A: Each tablet contains Sofosbuvir 400 mg and Velpatasvir 100 mg.

Q4: What are the common side effects of MyHep All?
A: Common side effects may include headache, fatigue, nausea, and insomnia. Most are mild and go away as the body adjusts to the medicine.

Q5: Can MyHep All be used with other Hepatitis C drugs?
A: In some cases, your doctor may prescribe additional medication, such as Ribavirin, depending on your condition and history. Always follow your doctor’s recommendations.

Q6: Do I need to avoid any substances while taking MyHep All?
A: It’s best to avoid alcohol during treatment as it may worsen liver function. Also, avoid medications like antacids or drugs that reduce stomach acid, as they may reduce the effectiveness of Velpatasvir.

Q7: Is MyHep All suitable for people co-infected with HIV?
A: Yes, MyHep All has been shown to be safe and effective in patients co-infected with HIV. However, potential drug interactions must be managed by a healthcare provider.

Q8: Can I stop taking MyHep All if I feel better?
A: No. You should complete the full course of therapy, usually 12 weeks, to ensure the virus is completely eradicated and prevent resistance.

Q9: What should I do if I miss a dose?
A: Take the missed dose as soon as possible. If it’s near the time for the next dose, skip the missed one. Do not double up doses to make up for a missed tablet.

Q10: Is a prescription required for MyHep All?
A: Yes, MyHep All is a prescription medication and should only be taken under a doctor’s supervision after evaluation of your Hepatitis C condition.